Micafungin Accord (Micafungin)

Micafungin blocks the enzyme β‑(1,3)‑D‑glucan synthase, preventing the synthesis of β‑(1,3)‑D‑glucan, an essential structural component of the fungal cell wall. This disruption weakens the wall, leading to cell lysis and death of the fungus.

The specific dose and duration of Micafungin Accord are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and other clinical factors.

Safety data for micafungin in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Micafungin belongs to the echinocandin class, which targets the fungal cell wall, unlike azoles that inhibit ergosterol synthesis. Echinocandins are generally effective against Candida species, including some azole‑resistant strains, and have a lower risk of drug‑drug interactions compared with many azoles.

Micafungin Accord should be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution to maintain stability.

Micafungin Accord is given as an intravenous injection. The infusion is typically administered over a period of 30‑60 minutes, depending on the clinical protocol and patient tolerance, under the supervision of qualified healthcare personnel.

Serious risks include hepatotoxicity, severe hypersensitivity reactions such as anaphylaxis, and infusion‑related events like hypotension or respiratory distress. Patients should be monitored for signs of liver dysfunction and allergic responses throughout therapy.

Micafungin Accord is contraindicated in patients with known hypersensitivity to micafungin or any component of the formulation. Caution is also advised for individuals with severe hepatic impairment, unless the prescriber determines that benefits outweigh risks.